Patients whose tumor is still Her-2/neu-overexpressing will likely be sensitive to continued targeted treatment against Her-2/neu-overexpressing GC/GEJ cancer and may benefit from combination with HER-Vaxx and pembrolizumab due to the earlier described upregulation of PD-L1 and potential synergy between the these agents. This evidence concerns the gene CD274 and neoplasm.